The Cellectis stem cells Business Unit combines two Cellectis Group companies dedicated to stem cell technology. These are Ectycell, based at the Evry Genopole (France), and Cellartis, based in Gothenburg (Sweden), which was acquired by Cellectis in November 2011.
Cellartis AB is a Swedish biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine
Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
Cellartis is also the world's largest single commercial source of ethically derived hES cell lines and has developed more than 30 ethically derived cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future.
Cellartis is located in state of the art facilities in Göteborg, Sweden. The laboratories are prepared to meet the EU and US guidelines for current Good Manufacturing Practice (cGMP).